AbbVie presents Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis at EADV 2026

By Public Technologies
  • AbbVie flagged new dermatology trial and real-world results slated for presentation at the 2026 EADV Congress in Vienna, Sept. 30-Oct. 3.
  • Late-breaking Phase 2 findings for investigational zumilokibart in moderate-to-severe atopic dermatitis are set to outline efficacy and safety.
  • Late-breaking data for investigational lutikizumab in hidradenitis suppurativa are expected to show activity against key inflammatory drivers.
  • Updated evidence for Skyrizi and Rinvoq across multiple immune-mediated skin diseases is due to reinforce performance across broader patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300100PR_NEWS_USPR_____CG57265) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.